Strata Skin SciencesSSKN
SSKN
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
7% more capital invested
Capital invested by funds: $3.32M [Q3] → $3.54M (+$221K) [Q4]
0.29% more ownership
Funds ownership: 28.95% [Q3] → 29.24% (+0.29%) [Q4]
11% less funds holding
Funds holding: 19 [Q3] → 17 (-2) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$6
121%
upside
Avg. target
$6
121%
upside
High target
$6
121%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Anthony Vendetti 41% 1-year accuracy 7 / 17 met price target | 121%upside $6 | Buy Initiated | 27 Feb 2025 |
Financial journalist opinion
Based on 4 articles about SSKN published over the past 30 days
Neutral
Seeking Alpha
2 hours ago
STRATA Skin Sciences, Inc. (SSKN) Q4 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:00 PM ET STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q4 2024 Earnings Conference Call March 27, 2025, 16:30 PM ET Company Participants Dolev Rafaeli - CEO John Gillings - VP of Finance Louie Toma - CORE IR Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jeremy Pearlman - Maxim Group Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences, Inc. Fourth Quarter and Year End 2024 Financial Results and Corporate Update Conference Call.
Neutral
GlobeNewsWire
9 hours ago
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update
HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update.
Neutral
GlobeNewsWire
6 days ago
STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update
HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close.
Neutral
GlobeNewsWire
1 week ago
STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light
HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the results of a newly published study in Japan that further validates the technological advantages of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology over other sources of UVB light that are less accurate, lack the repetition rate and/or fluence capabilities of an Excimer Light for treating Vitiligo, Psoriasis, Alopecia Areata and Atopic Dermatitis. The study, titled “Excimer Laser Penetrates Deeper into Hair Follicles and Activates More Melanocyte Lineage Cells than Excimer Light,” authored by distinguished researchers from the Nippon Medical School and published in the peer reviewed Journal of Nippon Medical School, demonstrates that despite the two devices producing same 308-nm wavelength, the distinct technological characteristics between two devices can have significant impact on the clinical outcomes. Notably, the excimer laser exhibits laser properties (monochromatic coherent light) and unique device specifications (a high frequency of 400 Hz and a remarkably high irradiance that leads to cellular differences such as deeper penetration, greater activation of melanocyte lineage cells (melanocyte stem cells (McSCs) and melanoblasts) resulting in superior clinical outcomes in terms of greater pigmentation and fewer epidermal side effects relative to excimer light. This study provides further scientific evidence that the modality generating UVB light has significant impact on the clinical outcomes of a device.
Positive
Zacks Investment Research
2 months ago
Why Fast-paced Mover Strata Skin Sciences (SSKN) Is a Great Choice for Value Investors
Strata Skin Sciences (SSKN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Neutral
GlobeNewsWire
3 months ago
STRATA Skin Sciences to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
HORSHAM, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and Chief Executive Officer Dr. Dolev Rafaeli will participate in the Benchmark Company 13th Annual Discovery Investor Conference that is being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Neutral
Seeking Alpha
4 months ago
STRATA Skin Sciences, Inc. (SSKN) Q3 2024 Earnings Call Transcript
STRATA Skin Sciences, Inc. (SSKN) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
HORSHAM, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2024 and provides a corporate update.
Neutral
GlobeNewsWire
4 months ago
STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group
HORSHAM, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that the United States District Court for the Eastern District of Pennsylvania entered a court order in favor of the Company in its complaint against LaserOptek America Corp. (“LaserOptek”), Monarch Aesthetic Services, Inc. d/b/a Monarch Laser Services (“MLS”), and The Pinnacle Health Group (“Pinnacle”), collectively referred to as the “Defendants.”
Neutral
GlobeNewsWire
4 months ago
STRATA Skin Sciences to Report Third Quarter 2024 Financial Results on November 13, 2024 and Provide Corporate Update
HORSHAM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2024 financial results on Wednesday, November 13, 2024 after the market close.
Charts implemented using Lightweight Charts™